MedWatch

Local biopharma executives praise the Danish business environment

Preliminary results from a large-scale analysis show that local executives would recommend others to invest in Denmark, when it comes to biotech and pharmaceuticals.

Foto: colourbox

Does Denmark deserve investments from global bio-pharma companies? Yes, very much so. In fact, no other country can measure up to Denmark, if you ask the local biopharma executives themselves.

The information appears in the preliminary, but highly detailed, analysis; Biopharmaceutical and Investment Survey (BCI), which “is a new tool for assessing the biomedical sector in a country or region,” write the consultants from the company Pugatch Consilium, who are behind the analysis.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier